__NUXT_JSONP__("/drugs/Ripertamab", (function(a,b,c){return {data:[{drug:{slug:a,emaEpar:[],fdaDrugLabel:[],id:a,nciThesaurus:{casRegistry:"2249927-04-4",chebiId:b,chemicalFormula:b,definition:"A chimeric monoclonal antibody directed against human CD20, with potential antineoplastic activity. Ripertamab binds to the B-cell-specific cell surface antigen CD20, which triggers an immune response against CD20-positive B-cells, leading to apoptosis. CD20, a non-glycosylated cell surface phosphoprotein, is exclusively expressed on B-cells during most stages of B-cell development and is often overexpressed in B-cell malignancies.",fdaUniiCode:"URS0374MIV",identifier:"C122680",preferredName:a,semanticType:"Immunologic Factor",subclassOf:["C129822","C141215"],synonyms:["Anti-CD20 Monoclonal Antibody SCT400","RIPERTAMAB",a,"SCT400"]},dir:"\u002Fdrugs",path:"\u002Fdrugs\u002FRipertamab",extension:".json",createdAt:c,updatedAt:c}}],fetch:{},mutations:void 0}}("Ripertamab","","2021-10-30T13:29:57.403Z")));